- Gastroenterology Advisor

Crohn disease


Latest Articles

Intravenous Vedolizumab Associated With Improved Outcomes in Crohn Disease

Vedolizumab has demonstrated efficacy among individuals with moderate to severe active Crohn disease, according to a study recently published in Gastroenterology. Improvements were observed in radiologic, histologic, and endoscopic outcomes.  This open-label, phase-3b trial (VERSIFY; ClinicalTrials.gov identifier: NCT02425111) included 101 individuals who had experienced active Crohn disease for 3 months or more between March 2015…